[go: up one dir, main page]

AR129859A2 - Compuesto de bis(fluoralquil)-1,4-benzodiacepinona - Google Patents

Compuesto de bis(fluoralquil)-1,4-benzodiacepinona

Info

Publication number
AR129859A2
AR129859A2 ARP230101776A ARP230101776A AR129859A2 AR 129859 A2 AR129859 A2 AR 129859A2 AR P230101776 A ARP230101776 A AR P230101776A AR P230101776 A ARP230101776 A AR P230101776A AR 129859 A2 AR129859 A2 AR 129859A2
Authority
AR
Argentina
Prior art keywords
bis
fluoralkyl
compound
benzodiazepinone
benzodiazepinone compound
Prior art date
Application number
ARP230101776A
Other languages
English (en)
Inventor
Ashvinikumar Gavai
Claude Quesnelle
Soong Kim
- Lee Francis Hoon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45894701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR129859(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR129859A2 publication Critical patent/AR129859A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Compuesto de bis(fluoralquil)-1,4-benzodiacepinona que tiene la fórmula (1) donde: R¹ es -CH₂CF₃ o -CH₂CH₂CF₃; R² es -CH₂CF₃, -CH₂CH₂CF₃ o -CH₂CH₂CH₂CF₃; R³ es H, -CH₃ o -CD₃; cada Rᵃ es independientemente F, Cl, -CN, -OCH₃ y/o -NHCH₂CH₂OCH₃ y z es 0, 1 o 2. Reivindicación 9: El compuesto de acuerdo con la reivindicación 8, caracterizado porque es de fórmula (2).
ARP230101776A 2011-03-22 2023-07-07 Compuesto de bis(fluoralquil)-1,4-benzodiacepinona AR129859A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161466238P 2011-03-22 2011-03-22

Publications (1)

Publication Number Publication Date
AR129859A2 true AR129859A2 (es) 2024-10-02

Family

ID=45894701

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120100932A AR085471A1 (es) 2011-03-22 2012-03-21 Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
ARP230101776A AR129859A2 (es) 2011-03-22 2023-07-07 Compuesto de bis(fluoralquil)-1,4-benzodiacepinona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120100932A AR085471A1 (es) 2011-03-22 2012-03-21 Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona

Country Status (32)

Country Link
US (2) US8629136B2 (es)
EP (1) EP2688873B1 (es)
JP (1) JP5873923B2 (es)
KR (1) KR101948347B1 (es)
CN (1) CN103717576B (es)
AR (2) AR085471A1 (es)
AU (1) AU2012230904B2 (es)
BR (1) BR112013024059B1 (es)
CA (1) CA2830902C (es)
CL (1) CL2013002690A1 (es)
CO (1) CO6771446A2 (es)
CY (1) CY1116423T1 (es)
DK (1) DK2688873T3 (es)
EA (1) EA022530B1 (es)
ES (1) ES2534080T3 (es)
HR (1) HRP20150273T1 (es)
IL (1) IL228534A (es)
MA (1) MA35036B1 (es)
MX (1) MX2013010420A (es)
MY (1) MY161233A (es)
PE (1) PE20140626A1 (es)
PH (1) PH12013501738B1 (es)
PL (1) PL2688873T3 (es)
PT (1) PT2688873E (es)
RS (1) RS53843B1 (es)
SG (1) SG193555A1 (es)
SI (1) SI2688873T1 (es)
SM (1) SMT201500091B (es)
TN (1) TN2013000372A1 (es)
TW (1) TWI530489B (es)
UY (1) UY33961A (es)
WO (1) WO2012129353A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
JP2015534554A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
EP2897942B1 (en) * 2012-09-21 2016-08-31 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors
EP2897946B1 (en) * 2012-09-21 2016-11-16 Bristol-Myers Squibb Company N-substituted bis(fluoroalkkyl)-1,4-benzodiazepinone compounds as notch inhibitors
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
WO2014047370A1 (en) * 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
EP2897941B1 (en) * 2012-09-21 2016-09-07 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
EP2897944B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
JP2015529252A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ フルオロアルキル−１，４−ベンゾジアゼピノン化合物
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
CN105101968A (zh) 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
CN103435562B (zh) * 2013-08-26 2016-02-24 华东理工大学 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
EP3212233B1 (en) * 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016066115A1 (zh) * 2014-10-31 2016-05-06 厦门大学 取代杂环衍生物、其制备方法和用途
CN104356082B (zh) * 2014-10-31 2016-07-13 厦门大学 一类取代杂环衍生物及其制备方法
CN104352488B (zh) * 2014-10-31 2016-08-31 厦门大学 一类取代杂环衍生物在制备治疗疼痛药物中的应用
CN104892532B (zh) * 2015-05-20 2017-09-08 成都理工大学 手性3‑取代1,3,4,5‑四氢‑1,4‑苯二氮*‑2‑酮的合成工艺
RS63653B1 (sr) 2015-07-22 2022-11-30 Enanta Pharm Inc Benzodiazepinski derivati kao inhibitori rsv
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
WO2017123884A1 (en) 2016-01-15 2017-07-20 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EP3429571B1 (en) 2016-03-15 2025-10-08 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2018152413A1 (en) 2017-02-16 2018-08-23 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
ES2817910T3 (es) * 2017-08-04 2021-04-08 Alzheimur 2012 S L Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
CN111343990B (zh) * 2017-11-13 2023-08-04 英安塔制药有限公司 苯并二氮杂䓬-2-酮和苯并氮杂䓬-2-酮衍生物的拆分方法
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019217250A1 (en) * 2018-05-06 2019-11-14 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
WO2019215585A1 (en) * 2018-05-06 2019-11-14 Ayala Pharmaceuticals Inc. Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
SG11202011327UA (en) * 2018-05-15 2020-12-30 Ayala Pharmaceuticals Inc Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma
BR112020023204A2 (pt) * 2018-05-15 2021-02-23 Bristol-Myers Squibb Company composições que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso dos mesmos
BR112020023975A2 (pt) * 2018-05-24 2021-02-23 Ayala Pharmaceuticals Inc. composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
IL317554A (en) 2018-06-01 2025-02-01 Novartis Ag Anti-BCMA binding molecules and their uses
UY38614A (es) 2019-03-18 2020-10-30 Enanta Pharm Inc Derivados de benzodiazepinas como inhibidores del rsv
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
JP2022533100A (ja) * 2019-05-15 2022-07-21 アヤラ ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
TW202115114A (zh) 2019-06-24 2021-04-16 瑞士商諾華公司 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2022003984A (es) 2019-10-04 2022-07-27 Enanta Pharm Inc Compuestos heterociclicos antivirales.
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
IL301060A (en) 2020-09-03 2023-05-01 Bristol Myers Squibb Co Polymorphs of bis(fluoroalkyl)-1,4-benzodiazepine compounds and their uses
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
WO2022122667A1 (en) 2020-12-07 2022-06-16 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
KR20230161976A (ko) 2021-02-26 2023-11-28 이난타 파마슈티칼스, 인코포레이티드 항바이러스성 헤테로사이클릭 화합물
EP4346816A2 (en) 2021-06-02 2024-04-10 Cellestia Biotech AG Compounds for use in a method for treating an autoimmune and inflammatory disease
US20250000870A1 (en) 2021-11-08 2025-01-02 Cellestia Biotech Ag Pharmaceutical Combinations for Treating Cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
WO2024145306A1 (en) * 2022-12-28 2024-07-04 Ayala Pharmaceuticals Inc. Intermediate salt for the preparation of bis(fluoroalkyl) benzodiazepinone compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
AU2555997A (en) * 1996-04-03 1997-10-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5852010A (en) 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
DE69926254D1 (de) 1998-11-12 2005-08-25 Bristol Myers Squibb Pharma Co Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
CA2347671A1 (en) 1998-12-24 2000-07-06 Dupont Pharmaceuticals Company Succinoylamino benzodiazepines as inhibitors of a.beta. protein production
MXPA01011052A (es) 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
AU7997700A (en) 1999-10-08 2001-04-23 Du Pont Pharmaceuticals Company Amino lactam sulfonamides as inhibitors of abeta protein production
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
JP2003520266A (ja) 2000-01-24 2003-07-02 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害薬
JP2003523345A (ja) 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
WO2001074796A1 (en) 2000-03-31 2001-10-11 Bristol-Myers Squibb Pharma Company SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
CA2404023A1 (en) 2000-04-03 2001-10-11 Richard E. Olson Cyclic lactams as inhibitors of a.beta. protein production
US6713476B2 (en) 2000-04-03 2004-03-30 Dupont Pharmaceuticals Company Substituted cycloalkyls as inhibitors of a beta protein production
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
JP2004500419A (ja) 2000-04-11 2004-01-08 デュポン　ファーマシューティカルズ　カンパニー Ａβタンパク質産生阻害剤としての置換ラクタム
AU2001261728A1 (en) 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
GB0012671D0 (en) * 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
HK1049333A1 (zh) 2000-06-01 2003-05-09 Bristol-Myers Squibb Pharma Company 以环状琥珀酸酯代替内酰胺，作为制造Aβ蛋白质的抑制剂
US7001901B2 (en) 2002-08-27 2006-02-21 Bristol-Myers Squibb Company Tetrazolylpropionamides as inhibitors of Aβ protein production
NZ538870A (en) 2002-09-20 2007-04-27 Arrow Therapeutics Ltd Benzodiazepine derivatives and pharmaceutical compositions containing them
MXPA05008172A (es) 2003-02-04 2005-10-05 Hoffmann La Roche Derivados de malonamida como inhibidores gamma-secretasa.
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
BRPI0413533A (pt) 2003-09-09 2006-10-10 Hoffmann La Roche derivados de malonamida que bloqueiam a atividade de gama-secretase
EP1795198A1 (en) 2005-12-09 2007-06-13 Hubrecht Laboratorium Treatment of Barret's esophagus
CA2644136A1 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
MX2008012136A (es) 2006-03-27 2008-10-03 Hoffmann La Roche Derivados de malonamida como inhibidores de gama secretasa.
WO2008034735A2 (en) 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives
AU2008287124B2 (en) 2007-08-14 2013-06-06 Eli Lilly And Company Azepine derivatives as gamma-secretase inhibitors
BRPI0906831A2 (pt) 2008-01-11 2019-09-24 Hoffmann La Roche uso de um inibidor de gama-secretase para tratamento de câncer
WO2011060051A1 (en) 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma
US20120225860A1 (en) 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor

Also Published As

Publication number Publication date
PE20140626A1 (es) 2014-05-30
MY161233A (en) 2017-04-14
MX2013010420A (es) 2013-10-01
AU2012230904B2 (en) 2016-03-31
US8822454B2 (en) 2014-09-02
CL2013002690A1 (es) 2014-02-14
WO2012129353A1 (en) 2012-09-27
US20140100365A1 (en) 2014-04-10
TWI530489B (zh) 2016-04-21
EA022530B1 (ru) 2016-01-29
BR112013024059B1 (pt) 2022-01-25
CA2830902C (en) 2019-10-29
US20120245151A1 (en) 2012-09-27
PL2688873T3 (pl) 2015-06-30
EA201391324A1 (ru) 2014-03-31
KR101948347B1 (ko) 2019-02-14
CN103717576A (zh) 2014-04-09
HK1189218A1 (en) 2014-05-30
JP5873923B2 (ja) 2016-03-01
TN2013000372A1 (en) 2015-01-20
ES2534080T3 (es) 2015-04-17
NZ616876A (en) 2014-08-29
AR085471A1 (es) 2013-10-02
PH12013501738B1 (en) 2019-03-13
US8629136B2 (en) 2014-01-14
CO6771446A2 (es) 2013-10-15
IL228534A (en) 2017-02-28
TW201309656A (zh) 2013-03-01
EP2688873B1 (en) 2015-01-21
HRP20150273T1 (hr) 2015-06-19
CY1116423T1 (el) 2017-02-08
EP2688873A1 (en) 2014-01-29
SMT201500091B (it) 2015-05-05
SI2688873T1 (sl) 2015-04-30
SG193555A1 (en) 2013-11-29
KR20140027956A (ko) 2014-03-07
CA2830902A1 (en) 2012-09-27
PT2688873E (pt) 2015-04-14
JP2014511840A (ja) 2014-05-19
UY33961A (es) 2012-09-28
MA35036B1 (fr) 2014-04-03
AU2012230904A1 (en) 2013-11-07
BR112013024059A2 (pt) 2016-12-06
CN103717576B (zh) 2015-11-25
DK2688873T3 (en) 2015-04-27
IL228534A0 (en) 2013-12-31
RS53843B1 (sr) 2015-08-31
PH12013501738A1 (en) 2013-10-07

Similar Documents

Publication Publication Date Title
AR129859A2 (es) Compuesto de bis(fluoralquil)-1,4-benzodiacepinona
EP3895643C0 (en) USE OF ALTERNATIVE ELECTRIC FIELDS TO INCREASE THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
JOP20180102B1 (ar) مركب صيدلاني
TR201900038T4 (tr) GPR6'nın tetrahidropiridopirazin modülatörleri.
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UA110338C2 (xx) Хімічні сполуки
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
CO7111287A2 (es) Composiciones plaguicidas y procesos relacionados
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
FR3004467B1 (fr) Fabrication d'une elpasolite stoechiometrique
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
EP2973167A4 (en) PROCESS FOR SECURING THE USE OF UNIQUE PASSWORDS
CO7111313A2 (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
EA201590321A1 (ru) Дейтерированный барицитиниб
UY34234A (es) Inhibidores de la replicación de los virus de la gripe
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CR20150661A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
AR100233A1 (es) Composición de limpieza
CR20130539A (es) Triazolopiridinas
AR097866A1 (es) Derivados de 4-azaindol